
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems has demonstrated substantial growth, as indicated by its increase in employee count to 1,333 in 2025 from 1,246 in 2024, reflecting an expanding operational capacity. The company's strategic focus on marketing is evidenced by a significant 21% increase in advertising expenses, reaching $114.9 million in 2025, suggesting an aggressive approach to drive sales and market penetration. Furthermore, the expected return to double-digit sales growth in the global hypoglossal nerve stimulation (HGNS) market, along with projected profitability improvements in 2026, supports a favorable outlook for the firm's financial performance.
Bears say
Inspire Medical Systems Inc. has lowered its revenue guidance for fiscal year 2026 from a range of $1,003-1,013 million to $950-1,000 million, reflecting anticipated challenges related to reimbursement and coding uncertainties. The company is facing significant headwinds, particularly due to a deceleration in domestic growth and the potential disincentives for ENT specialists to perform necessary procedures in light of evolving reimbursement frameworks. As uncertainty persists regarding the company's near-term growth outlook, it is suggested that a lower valuation multiple is warranted to account for these challenges.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares